Treats Amblyopia. ANDA 219996, held by Gland. Atropine Sulfate.
As of Nov 16, 2026, ANDA 219996 (Atropine Sulfate), held by Gland, was first approved by FDA on Jul 31, 2026, with 0 approved supplements and 0 published complete response letters.
Atropine Sulfate Ophthalmic Solution, 1% is indicated in adults and pediatric patients aged three months and older for: 1.1 Cycloplegia 1.2 Mydriasis 1.3 Penalization of the Healthy Eye in the Treatment of Amblyopia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atropine Sulfate1% · solution/drops;ophthalmic | Atropine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters